E. Ohman J or Asset Management AB Has $2.03 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

E. Ohman J or Asset Management AB raised its holdings in Edwards Lifesciences Co. (NYSE:EW) by 10.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 27,355 shares of the medical research company’s stock after acquiring an additional 2,600 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Edwards Lifesciences were worth $2,025,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of EW. Wellington Management Group LLP boosted its position in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. Jennison Associates LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $555,939,000. Assenagon Asset Management S.A. grew its stake in Edwards Lifesciences by 475.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after purchasing an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in Edwards Lifesciences by 239.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after purchasing an additional 2,606,950 shares in the last quarter. Finally, Seilern Investment Management Ltd acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $109,490,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Citigroup raised their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price target for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Royal Bank of Canada increased their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, Barclays upped their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $79.19.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,000 shares of company stock valued at $547,430. 1.27% of the stock is owned by insiders.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $71.33 on Wednesday. The firm has a market capitalization of $42.07 billion, a P/E ratio of 10.29, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business’s fifty day simple moving average is $72.49 and its 200 day simple moving average is $69.63. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.